Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Reviews on Recent Clinical Trials
  4. Volume 20, Issue 2
  5. Article
Volume 20, Issue 2
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Angioedema is a health issue that affects parts of the body like the upper pulmonary and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous membranes, or both. The swelling usually lasts a few hours to 72 hours and may appear as non-puritic, subcutaneous, or submucosal organ edema. It is characterized by localized swelling brought on by the release of histamine. Itching is rare, and usual areas of appearance include the hands, feet, face, and genitalia, with periorbital swelling being the most often. The main objective of this review article is to study in brief the classifications, etiology, pathophysiology, and clinical trial data by describing the recent advancement in the treatment of angioedema. Various research articles obtained from different journals indexed under Scopus and SCI were used to prepare the review article and for illustrative work software such as Biorender and Microsoft Word was used. Histamine-mediated angioedema, linked to allergic reactions, coexists with urticaria. Bradykinin-mediated angioedema, exemplified by hereditary angioedema and acquired forms, lacks urticaria. Idiopathic angioedema, with uncertain etiology. Imitated angioedema results from non-IgE-mediated reactions, often induced by medications. It is a complicated medical condition with a variety of causes and mechanisms. Over time, outcomes for patients have been greatly improved by a growing understanding of its etiology, pathophysiology, and available treatments. The field of medical treatment for this difficult problem is always changing, and this is partly due to clinical trials.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871307432240930051749
2024-10-11
2025-07-11

  • From This Site

    /content/journals/rrct/10.2174/0115748871307432240930051749
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KaplanA.P. Angioedema.World Allergy Organ. J.20081610311310.1097/WOX.0b013e31817aecbe23282406
     [Google Scholar]
  2. KaplanA.P. GreavesM.W. Angioedema.J. Am. Acad. Dermatol.200553337338810.1016/j.jaad.2004.09.03216112343
     [Google Scholar]
  3. GreavesM. LawlorF. Angioedema: Manifestations and management.J. Am. Acad. Dermatol.199125115516510.1016/0190‑9622(91)70183‑31869690
     [Google Scholar]
  4. ReshefA. KidonM. LeibovichI. The story of angioedema: From Quincke to bradykinin.Clin. Rev. Allergy Immunol.201651212113910.1007/s12016‑016‑8553‑827287037
     [Google Scholar]
  5. GillP. BetschelS.D. The clinical evaluation of angioedema.Immunol. Allergy Clin. North Am.201737344946610.1016/j.iac.2017.04.00728687102
     [Google Scholar]
  6. BernsteinJ.A. MoellmanJ. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema.Int. J. Emerg. Med.2012513910.1186/1865‑1380‑5‑3923131076
     [Google Scholar]
  7. CicardiM. AbererW. BanerjiA. BasM. BernsteinJ.A. BorkK. CaballeroT. FarkasH. GrumachA. KaplanA.P. RiedlM.A. TriggianiM. ZanichelliA. ZurawB. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology) Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the hereditary angioedema international working group.Allergy201469560261610.1111/all.1238024673465
     [Google Scholar]
  8. ZuberbierT. AbererW. AseroR. Abdul LatiffA.H. BakerD. Ballmer-WeberB. BernsteinJ.A. Bindslev-JensenC. BrzozaZ. Buense BedrikowR. CanonicaG.W. ChurchM.K. CraigT. DanilychevaI.V. DresslerC. EnsinaL.F. Giménez-ArnauA. GodseK. GonçaloM. GrattanC. HebertJ. HideM. KaplanA. KappA. KatelarisC.H. KocatürkE. KulthananK. Larenas-LinnemannD. LeslieT.A. MagerlM. Mathelier-FusadeP. MeshkovaR.Y. MetzM. NastA. NettisE. Oude-ElberinkH. RosumeckS. SainiS.S. Sánchez-BorgesM. Schmid-GrendelmeierP. StaubachP. SussmanG. ToubiE. VenaG.A. VestergaardC. WediB. WernerR.N. ZhaoZ. MaurerM. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.Allergy20187371393141410.1111/all.1339729336054
     [Google Scholar]
  9. KananiA. BetschelS.D. WarringtonR. Urticaria and angioedema.Allergy Asthma Clin. Immunol.201814S2Suppl. 25910.1186/s13223‑018‑0288‑z30263036
     [Google Scholar]
  10. PoddigheD. De AmiciM. MarsegliaG.L. Spontaneous (autoimmune) chronic urticaria in children: Current evidences, diagnostic pitfalls and therapeutic management.Recent Pat. Inflamm. Allergy Drug Discov.2016101343910.2174/1872213X1066616021916350226899967
     [Google Scholar]
  11. KolkhirP. MuñozM. AseroR. FerrerM. KocatürkE. MetzM. XiangY.K. MaurerM. Autoimmune chronic spontaneous urticaria.J. Allergy Clin. Immunol.202214961819183110.1016/j.jaci.2022.04.01035667749
     [Google Scholar]
  12. WuM.A. PeregoF. ZanichelliA. CicardiM. Angioedema phenotypes: Disease expression and classification.Clin. Rev. Allergy Immunol.201651216216910.1007/s12016‑016‑8541‑z27113957
     [Google Scholar]
  13. VestergaardC. DeleuranM. Chronic spontaneous urticaria: Latest developments in aetiology, diagnosis and therapy.Ther. Adv. Chronic Dis.20156630431310.1177/204062231560395126568807
     [Google Scholar]
  14. LoVerdeD. FilesD.C. KrishnaswamyG. Angioedema.Crit. Care Med.201745472573510.1097/CCM.000000000000228128291095
     [Google Scholar]
  15. NajibU. SheikhJ. An update on acute and chronic urticaria for the primary care provider.Postgrad. Med.2009121114115110.3810/pgm.2009.01.196619179823
     [Google Scholar]
  16. CaballeroT. FerrerM. GuilarteM. Classification and treatment of angioedema without wheals: A spanish delphi consensus.Am. J. Clin. Dermatol.202324113514110.1007/s40257‑022‑00735‑736310330
     [Google Scholar]
  17. GhablyJ. SalehH. VyasH. PeirisE. MisraN. KrishnaswamyG. Paul Ehrlich’s mastzellen: A historical perspective of relevant developments in mast cell biology.Methods Mol Biol20151220310
     [Google Scholar]
  18. KrishnaswamyG. AjitawiO. ChiD.S. The human mast cell: An overview.Methods Mol Biol.2005315133410.1385/1‑59259‑967‑2:013
     [Google Scholar]
  19. BovaM. De FeoG. ParenteR. De PasqualeT. GravanteC. PucciS. NettisE. TriggianiM. Hereditary and acquired angioedema: Heterogeneity of pathogenesis and clinical phenotypes.Int. Arch. Allergy Immunol.2018175312613510.1159/00048631229393169
     [Google Scholar]
  20. MansiM. ZanichelliA. CoerezzaA. SuffrittiC. WuM.A. VacchiniR. StieberC. CichonS. CicardiM. Presentation, diagnosis and treatment of angioedema without wheals: A retrospective analysis of a cohort of 1058 patients.J. Intern. Med.2015277558559310.1111/joim.1230425196353
     [Google Scholar]
  21. FeigheryC. Antibody molecules: Mediators of disease and diagnostic tools.Ir. J. Med. Sci.19891581024525210.1007/BF029437002695493
     [Google Scholar]
  22. MiltonJ.L. On giant urticaria.Edinburgh Med. J.187622651352629640127
     [Google Scholar]
  23. GülbaharO. GermenisA.E. Rediscovery of a forgotten disease: Hereditary Angioedema.Balkan Med. J.2021382687210.5152/balkanmedj.2021.2003033593720
     [Google Scholar]
  24. KamathR.R. RaiS.J. Quincke’s disease: A case report.Egypt. J. Otolaryngol.20203614410.1186/s43163‑020‑00048‑8
     [Google Scholar]
  25. MargaglioneM. D’ApolitoM. SantocroceR. MaffioneA.B. Hereditary angioedema: Looking for bradykinin production and triggers of vascular permeability.Clin. Exp. Allergy201949111395140210.1111/cea.1350631574187
     [Google Scholar]
  26. BowenT. CicardiM. BorkK. ZurawB. FrankM. RitchieB. FarkasH. VargaL. ZingaleL.C. BinkleyK. WagnerE. AdomaitisP. BroszK. BurnhamJ. WarringtonR. KalicinskyC. MaceS. McCuskerC. SchellenbergR. CelesteL. HebertJ. ValentineK. PoonM.C. SerushagoB. NeurathD. YangW. LacuestaG. IssekutzA. HamedA. KamraP. DeanJ. KananiA. StarkD. RivardG.E. LeithE. TsaiE. WasermanS. KeithP.K. PageD. MarchesinS. LonghurstH.J. KreuzW. RusickeE. Martinez-SaguerI. Aygören-PürsünE. HarmatG. FüstG. LiH. BouilletL. CaballeroT. MoldovanD. SpäthP.J. Smith-FoltzS. NagyI. NielsenE.W. BucherC. NordenfeltP. XiangZ.Y. Hereditary angiodema: A current state-of-the-art review, VII: Canadian hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema.Ann. Allergy Asthma Immunol.20081001Suppl. 2S30S4010.1016/S1081‑1206(10)60584‑418220150
     [Google Scholar]
  27. PenskyJ. LevyL.R. LepowI.H. Partial purification of a serum inhibitor of C’1-esterase.J. Biol. Chem.196123661674167910.1016/S0021‑9258(19)63283‑713734157
     [Google Scholar]
  28. LandermanN.S. WebsterM.E. BeckerE.L. RatcliffeH.E. Hereditary angioneurotic edema.J. Allergy196233433034110.1016/0021‑8707(62)90032‑114461960
     [Google Scholar]
  29. RosenFS CharacheP PenskyJ DonaldsonV Hereditary angioneurotic edema: Two genetic variants.Science1965148367295795810.1126/science.148.3672.957
     [Google Scholar]
  30. FieldsT. GhebrehiwetB. KaplanA. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin.J. Allergy Clin. Immunol.1983721546010.1016/0091‑6749(83)90052‑06222104
     [Google Scholar]
  31. CaldwellJ.R. RuddyS. SchurP.H. AustenK.F. Acquired inhibitor deficiency in lymphosarcoma.Clin. Immunol. Immunopathol.197211395210.1016/0090‑1229(72)90006‑2
     [Google Scholar]
  32. ThompsonT. FrableM.A.S. Drug-induced, life-threatening angioedema revisited.Laryngoscope19931031101210.1288/00005537‑199301000‑000038380620
     [Google Scholar]
  33. IsrailiZ.H. HallW.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.Ann. Intern. Med.1992117323424210.7326/0003‑4819‑117‑3‑2341616218
     [Google Scholar]
  34. RiedlM.A. Hereditary angioedema with normal C1-INH (HAE type III).J. Allergy Clin. Immunol. Pract.20131542743210.1016/j.jaip.2013.06.00424565612
     [Google Scholar]
  35. BorkK. FrankJ. GrundtB. SchlattmannP. NussbergerJ. KreuzW. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).J. Allergy Clin. Immunol.200711961497150310.1016/j.jaci.2007.02.01217418383
     [Google Scholar]
  36. ZurawB.L. BusseP.J. WhiteM. JacobsJ. LumryW. BakerJ. CraigT. GrantJ.A. HurewitzD. BieloryL. CartwrightW.E. KoleilatM. RyanW. SchaeferO. ManningM. PatelP. BernsteinJ.A. FriedmanR.A. WilkinsonR. TannerD. KohlerG. GuntherG. LevyR. McClellanJ. RedheadJ. GussD. HeymanE. BlumensteinB.A. KalfusI. FrankM.M. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.N. Engl. J. Med.2010363651352210.1056/NEJMoa080553820818886
     [Google Scholar]
  37. HofstraJ.J. BuddeI.K. van TwuyverE. ChoiG. LeviM. LeebeekF.W.G. de MonchyJ.G.R. YpmaP.F. KeizerR.J. HuitemaA.D.R. StrengersP.F.W. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety.Clin. Immunol.2012142328029010.1016/j.clim.2011.11.00522197071
     [Google Scholar]
  38. FerdmanR.M. Urticaria and angioedema.Clin. Pediatr. Emerg. Med.200782728010.1016/j.cpem.2007.04.001
     [Google Scholar]
  39. GrumachA.S. Staubach-RenzP. VillaR.C. Diez-ZuluagaS. ReeseI. LumryW.R. Triggers of exacerbation in chronic urticaria and recurrent angioedema—prevalence and relevance.J. Allergy Clin. Immunol. Pract.2021962160216810.1016/j.jaip.2021.04.02334112472
     [Google Scholar]
  40. GeorgitisJ.W. FasanoM.B. Allergenic components of vaccines and avoidance of vaccination-related adverse events.Curr. Allergy Asthma Rep.200111111710.1007/s11882‑001‑0091‑611899279
     [Google Scholar]
  41. TemiñoV.M. PeeblesR.S.Jr The spectrum and treatment of angioedema.Am. J. Med.2008121428228610.1016/j.amjmed.2007.09.02418374684
     [Google Scholar]
  42. BowenT. CicardiM. FarkasH. BorkK. KreuzW. ZingaleL. VargaL. Martinez-SaguerI. Aygören-PürsünE. BinkleyK. ZurawB. DavisA.III HebertJ. RitchieB. BurnhamJ. CastaldoA. MenendezA. NagyI. HarmatG. BucherC. LacuestaG. IssekutzA. WarringtonR. YangW. DeanJ. KananiA. StarkD. McCuskerC. WagnerE. RivardG.E. LeithE. TsaiE. MacSweenM. LyangaJ. SerushagoB. LeznoffA. WasermanS. de SerresJ. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema.J. Allergy Clin. Immunol.2004114362963710.1016/j.jaci.2004.06.04315356569
     [Google Scholar]
  43. BernsteinJ.A. CremonesiP. HoffmannT.K. HollingsworthJ. Angioedema in the emergency department: A practical guide to differential diagnosis and management.Int. J. Emerg. Med.20171011510.1186/s12245‑017‑0141‑z28405953
     [Google Scholar]
  44. BowenT. CicardiM. FarkasH. BorkK. LonghurstH.J. ZurawB. Aygoeren-PürsünE. CraigT. BinkleyK. HebertJ. RitchieB. BouilletL. BetschelS. CogarD. DeanJ. DevarajR. HamedA. KamraP. KeithP.K. LacuestaG. LeithE. LyonsH. MaceS. MakoB. NeurathD. PoonM.C. RivardG.E. SchellenbergR. RowanD. RoweA. StarkD. SurS. TsaiE. WarringtonR. WasermanS. AmeratungaR. BernsteinJ. BjörkanderJ. BroszK. BroszJ. BygumA. CaballeroT. FrankM. FustG. HarmatG. KananiA. KreuzW. LeviM. LiH. Martinez-SaguerI. MoldovanD. NagyI. NielsenE.W. NordenfeltP. ReshefA. RusickeE. Smith-FoltzS. SpäthP. VargaL. XiangZ.Y. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.Allergy Asthma Clin. Immunol.2010612410.1186/1710‑1492‑6‑2420667127
     [Google Scholar]
  45. GrumachA.S. VeronezC.L. CsukaD. FarkasH. Angioedema without wheals: Challenges in laboratorial diagnosis.Front. Immunol.20211278573610.3389/fimmu.2021.78573634956216
     [Google Scholar]
  46. WeisM. Clinical review of hereditary angioedema: Diagnosis and management.Postgrad. Med.2009121611312010.3810/pgm.2009.11.207119940422
     [Google Scholar]
  47. PinesJ.M. PoarchK. HughesS. Recognition and differential diagnosis of hereditary angioedema in the emergency department.J. Emerg. Med.2021601354310.1016/j.jemermed.2020.09.04433218838
     [Google Scholar]
  48. TachdjianR. JohnstonD.T. Angioedema: Differential diagnosis and acute management.Postgraduate MedicineTaylor & Francis2021765770
     [Google Scholar]
  49. DepetriF. TedeschiA. CugnoM. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment.Eur. J. Intern. Med.20195981310.1016/j.ejim.2018.09.00430220453
     [Google Scholar]
  50. HudeyS.N. Westermann-ClarkE. LockeyR.F. Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema.J. Allergy Clin. Immunol. Pract.20175361061510.1016/j.jaip.2017.03.01728483314
     [Google Scholar]
  51. PattanaikD. LiebermanJ.A. Pediatric Angioedema.Curr. Allergy Asthma Rep.20171796010.1007/s11882‑017‑0729‑728791569
     [Google Scholar]
  52. Ertoy KaragolH.I. YilmazO. BakirtasA. TopalE. DemirsoyM.S. TurktasI. Angioedema without urticaria in childhood.Pediatr. Allergy Immunol.201324768569010.1111/pai.1211824028320
     [Google Scholar]
  53. ZingaleL.C. BeltramiL. ZanichelliA. MaggioniL. PappalardoE. CicardiB. CicardiM. Angioedema without urticaria: A large clinical survey.CMAJ200617591065107010.1503/cmaj.06053517060655
     [Google Scholar]
  54. ChaudhryT. HissariaP. WieseM. HeddleR. KetteF. SmithW.B. Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis.Intern. Med. J.201242666567110.1111/j.1445‑5994.2011.02601.x21981353
     [Google Scholar]
  55. SmolinskaS. Antolín-AmérigoD. PopescuF.D. Bradykinin metabolism and drug-induced angioedema.Int. J. Mol. Sci.202324141164910.3390/ijms24141164937511409
     [Google Scholar]
  56. CraigT. ZurawB. LonghurstH. CicardiM. BorkK. GrattanC. KatelarisC. SussmanG. KeithPK. YangW. HébertJ. HanzlikovaJ. Staubach-RenzP. Martinez-SaguerI. MagerlM. Aygören-PürsünE. FarkasH. ReshefA. KivityS. NeriS. CrisanI. CaballeroT. BaezaML. HernandezMD. LiH. LumryW. BernsteinJA. HussainI. AndersonJ. SchwartzLB. JacobsJ. ManningM. LevyD. RiedlM. ChristiansenS. FeuersengerH. PragstI. MycroftS. PawaskarD. JacobsI. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks.J Allergy Clin Immunol Pract.20197617931802
     [Google Scholar]
  57. BorkK. MengG. StaubachP. HardtJ. Hereditary angioedema: New findings concerning symptoms, affected organs, and course.Am. J. Med.2006119326727410.1016/j.amjmed.2005.09.06416490473
     [Google Scholar]
  58. a WahnV AbererW EberlW Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies.Eur J Pediatr2012171913394810.1007/s00431‑012‑1726‑422543566
     [Google Scholar]
  59. b SinertR LevyP BernsteinJA, Body R, Sivilotti ML, Moellman J, Schranz J, Baptista J, Kimura A, Nothaft W, CAMEO Study Group. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor–induced upper airway angioedema.The Journal of Allergy and Clinical Immunology: In Practice20175514029
     [Google Scholar]
  60. c StrakaBT RamirezCE ByrdJB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.Journal of Allergy and Clinical Immunology201714012428
     [Google Scholar]
  61. BeltramiL. ZingaleL.C. CarugoS. CicardiM. Angiotensin-converting enzyme inhibitor-related angioedema: How to deal with it.Expert Opin. Drug Saf.20065564364910.1517/14740338.5.5.64316907654
     [Google Scholar]
  62. ThornberryN.A. GallwitzB. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).Best Pract. Res. Clin. Endocrinol. Metab.200923447948610.1016/j.beem.2009.03.00419748065
     [Google Scholar]
  63. CicardiM. BergamaschiniL. ZingaleL.C. GioffréD. AgostoniA. Idiopathic nonhistaminergic angioedema.Am. J. Med.1999106665065410.1016/S0002‑9343(99)00123‑010378623
     [Google Scholar]
  64. LewisL.M. Angioedema: Etiology, pathophysiology, current and emerging therapies.J. Emerg. Med.201345578979610.1016/j.jemermed.2013.03.04523992848
     [Google Scholar]
  65. CicardiM. ZingaleL.C. ZanichelliA. DeliliersD.L. CacciaS. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.Expert Opin. Pharmacother.20078183173318110.1517/14656566.8.18.317318035961
     [Google Scholar]
  66. TerpstraF.G. KleijnM. KoendermanA.H.L. OverJ. van EngelenburgF.A.C. SchuitemakerH. van ’t WoutA.B. Viral safety of C1-inhibitor NF.Biologicals200735317318110.1016/j.biologicals.2006.08.00517071103
     [Google Scholar]
  67. WaytesA.T. RosenF.S. FrankM.M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.N. Engl. J. Med.1996334251630163410.1056/NEJM1996062033425038628358
     [Google Scholar]
  68. CicardiM. MannucciP.M. CastelliR. RumiM.G. AgostoniA. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.Transfusion199535320921210.1046/j.1537‑2995.1995.35395184276.x7878712
     [Google Scholar]
  69. De SerresJ. GrönerA. LindnerJ. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: A review.Transfus. Apheresis Sci.200329324725410.1016/j.transci.2003.08.00614572817
     [Google Scholar]
  70. PeregoF. WuM.A. ValerievaA. CacciaS. SuffrittiC. ZanichelliA. BergamaschiniL. CicardiM. Current and emerging biologics for the treatment of hereditary angioedema.Expert Opin. Biol. Ther.201919651752610.1080/14712598.2019.159558130912460
     [Google Scholar]
  71. WuM.A. ZanichelliA. MansiM. CicardiM. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.Expert Opin. Pharmacother.2016171274010.1517/14656566.2016.110430026512744
     [Google Scholar]
  72. CraigT.J. LevyR.J. WassermanR.L. BewtraA.K. HurewitzD. ObtułowiczK. ReshefA. RitchieB. MoldovanD. ShirovT. Grivcheva-PanovskaV. KiesslingP.C. KeineckeH.O. BernsteinJ.A. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.J. Allergy Clin. Immunol.2009124480180810.1016/j.jaci.2009.07.01719767078
     [Google Scholar]
  73. LunnM. SantosC. CraigT. Cinryze™ as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: Approval, efficacy and safety.J. Blood Med.2010116317010.2147/JBM.S957622282695
     [Google Scholar]
  74. Lyseng-WilliamsonK.A. Nanofiltered human C1 inhibitor concentrate (Cinryze®): A guide to its use in hereditary angioedema in the EU.Drugs Ther. Perspect.201329926026710.1007/s40267‑013‑0061‑9
     [Google Scholar]
  75. NicolaS. RollaG. BrussinoL. Breakthroughs in hereditary angioedema management: A systematic review of approved drugs and those under research.Drugs Context2019821260531645881
     [Google Scholar]
  76. CicardiM. BanerjiA. BrachoF. MalbránA. RosenkranzB. RiedlM. BorkK. LumryW. AbererW. BierH. BasM. GreveJ. HoffmannT.K. FarkasH. ReshefA. RitchieB. YangW. GrabbeJ. KivityS. KreuzW. LevyR.J. LugerT. ObtulowiczK. Schmid-GrendelmeierP. BullC. SitkauskieneB. SmithW.B. ToubiE. WernerS. AnnéS. BjörkanderJ. BouilletL. CillariE. HurewitzD. JacobsonK.W. KatelarisC.H. MaurerM. MerkH. BernsteinJ.A. FeigheryC. FloccardB. GleichG. HébertJ. KaatzM. KeithP. KirkpatrickC.H. LangtonD. MartinL. PichlerC. ResnickD. WomboltD. RomeroD.S.F. ZanichelliA. ArcoleoF. KnolleJ. KravecI. DongL. ZimmermannJ. RosenK. FanW.T. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.N. Engl. J. Med.2010363653254110.1056/NEJMoa090639320818888
     [Google Scholar]
  77. LumryW.R. LiH.H. LevyR.J. PotterP.C. FarkasH. MoldovanD. RiedlM. LiH. CraigT. BloomB.J. ReshefA. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.Ann. Allergy Asthma Immunol.20111076529537.e210.1016/j.anai.2011.08.01522123383
     [Google Scholar]
  78. AbererW. MaurerM. ReshefA. LonghurstH. KivityS. BygumA. CaballeroT. BloomB. NairN. MalbránA. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.Allergy201469330531410.1111/all.1230324438203
     [Google Scholar]
  79. FarkasH. DebreczeniM.L. KőhalmiK.V. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.Expert Opin. Investig. Drugs20182718710310.1080/13543784.2018.141532529226721
     [Google Scholar]
  80. ValerievaA. StaevskaM.T. Grivcheva-PanovskaV. JesenakM. KőhalmiK.V. HrubiskovaK. ZanichelliA. BellizziL. RelanA. HaklR. FarkasH. Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry.World Allergy Organ. J.202114410053510.1016/j.waojou.2021.10053533995818
     [Google Scholar]
  81. SyedY.Y. Lanadelumab: First global approval.Drugs201878151633163710.1007/s40265‑018‑0987‑230267321
     [Google Scholar]
  82. ValerievaA. NedevaD. YordanovaV. PetkovaE. StaevskaM. Therapeutic management of hereditary angioedema: Past, present, and future.Balkan Med. J.20213828910310.5152/balkanmedj.2021.2109433724190
     [Google Scholar]
  83. GuoY. ZhangH. LaiH. WangH. Chong-NetoH.J. ValleS.O.R. ZhuR. Long-term prophylaxis with androgens in the management of hereditary angioedema (HAE) in emerging countries.Orphanet J. Rare Dis.202217139910.1186/s13023‑022‑02536‑x36324138
     [Google Scholar]
  84. IaboniA. KananiA. LacuestaG. SongC. KanM. BetschelS.D. Impact of lanadelumab in hereditary angioedema: A case series of 12 patients in Canada.Allergy Asthma Clin. Immunol.20211717810.1186/s13223‑021‑00579‑634301329
     [Google Scholar]
  85. Bas¸M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.Expert Rev. Clin. Immunol.20128870771710.1586/eci.12.6723167682
     [Google Scholar]
  86. BusseP. KaplanA. Specific targeting of plasma kallikrein for treatment of hereditary angioedema: A revolutionary decade.J. Allergy Clin. Immunol. Pract.202210371672210.1016/j.jaip.2021.11.01134838707
     [Google Scholar]
  87. CicardiM. BorkK. CaballeroT. CraigT. LiH.H. LonghurstH. ReshefA. ZurawB. HAWK (Hereditary Angioedema International Working Group) Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group.Allergy201267214715710.1111/j.1398‑9995.2011.02751.x22126399
     [Google Scholar]
  88. FarkasH. Pharmacological management of hereditary angioedema with C1-inhibitor deficiency in pediatric patients.Paediatr. Drugs201820213515110.1007/s40272‑017‑0273‑x29214395
     [Google Scholar]
  89. TerreehorstI. ReitsmaS. CohnD.M. Current treatment of angioedema induced by ACE inhibitors.Curr. Treat. Options Allergy201961182610.1007/s40521‑019‑0203‑y
     [Google Scholar]
  90. JohnsonF. StenzlA. HofauerB. HepptH. EbertE.V. WollenbergB. LochbaumR. HahnJ. GreveJ. TrainottiS. A retrospective analysis of long-term prophylaxis with berotralstat in patients with hereditary angioedema and acquired c1-inhibitor deficiency—real-world data.Clin. Rev. Allergy Immunol.202365335436410.1007/s12016‑023‑08972‑237914894
     [Google Scholar]
  91. PowellJ. PiszczatoskiC. RubidoE. Orladeyo (Berotralstat): A novel oral therapy for the prevention of hereditary angioedema.Ann. Pharmacother.202256448849310.1177/1060028021103298234282650
     [Google Scholar]
  92. FarkasH. StobieckiM. PeterJ. KinaciyanT. MaurerM. Aygören-PürsünE. Kiani-AlikhanS. WuA. ReshefA. BygumA. FainO. HaginD. HuissoonA. JeseňákM. LindsayK. PanovskaV.G. SteinerU.C. ZubrinichC. BestJ.M. CornpropstM. DixD. DoboS.M. IoccaH.A. DesaiB. MurrayS.C. NagyE. SheridanW.P. Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.Clin. Transl. Allergy2021114e1203510.1002/clt2.1203534161665
     [Google Scholar]
  93. CaballeroT. FarkasH. BouilletL. BowenT. GompelA. FagerbergC. BjökanderJ. BorkK. BygumA. CicardiM. de CarolisC. FrankM. GooiJ.H.C. LonghurstH. Martínez-SaguerI. NielsenE.W. ObtulowitzK. PerriconeR. PriorN. C-1-INH Deficiency Working Group International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.J. Allergy Clin. Immunol.2012129230832010.1016/j.jaci.2011.11.02522197274
     [Google Scholar]
  94. ZanichelliA. VacchiniR. BadiniM. PennaV. CicardiM. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: A 21-month prospective study in a cohort of 103 patients.Allergy201166219219610.1111/j.1398‑9995.2010.02433.x21039598
     [Google Scholar]
  95. MoldovanD. BernsteinJ.A. CicardiM. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency.Immunotherapy20157773975210.2217/imt.15.4426250409
     [Google Scholar]
  96. MaurerM. MagerlM. BetschelS. AbererW. AnsoteguiI.J. Aygören-PürsünE. BanerjiA. BaraN.A. Boccon-GibodI. BorkK. BouilletL. BoysenH.B. BrodszkiN. BusseP.J. BygumA. CaballeroT. CancianM. CastaldoA.J. CohnD.M. CsukaD. FarkasH. GompelsM. GowerR. GrumachA.S. Guidos-FogelbachG. HideM. KangH.R. KaplanA.P. KatelarisC.H. Kiani-AlikhanS. LeiW.T. LockeyR.F. LonghurstH. LumryW. MacGinnitieA. MalbranA. Martinez SaguerI. Matta CamposJ.J. NastA. NguyenD. Nieto-MartinezS.A. PawankarR. PeterJ. PorebskiG. PriorN. ReshefA. RiedlM. RitchieB. SheikhF.R. SmithW.B. SpaethP.J. StobieckiM. ToubiE. VargaL.A. WellerK. ZanichelliA. ZhiY. ZurawB. CraigT. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update.World Allergy Organ. J.202215310062710.1016/j.waojou.2022.10062735497649
     [Google Scholar]
  97. CraigT.J. ReshefA. LiH.H. JacobsJ.S. BernsteinJ.A. FarkasH. YangW.H. StroesE.S.G. OhsawaI. TachdjianR. ManningM.E. LumryW.R. SaguerI.M. Aygören-PürsünE. RitchieB. SussmanG.L. AndersonJ. KawahataK. SuzukiY. StaubachP. TreudlerR. FeuersengerH. GlassmanF. JacobsI. MagerlM. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): A global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2023401103821079109010.1016/S0140‑6736(23)00350‑136868261
     [Google Scholar]
  98. CraigT. MagerlM. LevyD.S. ReshefA. LumryW.R. Martinez-SaguerI. JacobsJ.S. YangW.H. RitchieB. Aygören-PürsünE. KeithP.K. BusseP. FeuersengerH. PawaskarD. JacobsI. PragstI. DoyleM.K. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: A randomised, double-blind, placebo-controlled, phase 2 trial.Lancet20223991032894595510.1016/S0140‑6736(21)02225‑X35219377
     [Google Scholar]
  99. KalfusI. McDonaldA. QianS. Potency, selectivity, and exposure evaluation of ATN-249, a new oral kallikrein inhibitor for hereditary angioedema.J. Allergy Clin. Immunol.20171392AB37810.1016/j.jaci.2016.12.905
     [Google Scholar]
  100. KalfusI. OffmanE. McDonaldA. Pharmacokinetics and safety of ATN-249, a novel oral plasma kallikrein inhibitor for hereditary angioedema.West Soc Allergy, Asthma Immunol Maui, HI2019
     [Google Scholar]
  101. CrookeS.T. BakerB.F. XiaS. YuR.Z. VineyN.J. WangY. TsimikasS. GearyR.S. Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience.Nucleic Acid Ther.2019291163210.1089/nat.2018.075330570431
     [Google Scholar]
  102. FijenL.M. RiedlM.A. BordoneL. BernsteinJ.A. RaaschJ. TachdjianR. CraigT. LumryW.R. ManningM.E. AlexanderV.J. NewmanK.B. RevenkoA. BakerB.F. NanavatiC. MacLeodA.R. SchneiderE. CohnD.M. Inhibition of prekallikrein for hereditary angioedema.N. Engl. J. Med.2022386111026103310.1056/NEJMoa210932935294812
     [Google Scholar]
  103. LesageA. GibsonC. KnolleJ. GroenK. CrabbéR. LuP. Development of PHVS719: An oral extended-release bradykinin B2 receptor antagonist to prevent hereditary Angioedema attacks.Ann. Allergy Asthma Immunol.20221295S3110.1016/j.anai.2022.08.592
     [Google Scholar]
  104. SmithT.D. RiedlM.A. The future of therapeutic options for hereditary angioedema.Ann. Allergy Asthma Immunol.2024S1081-1206(24); 275-810.1016/j.anai.2024.04.02938679158
     [Google Scholar]
  105. BedianV. BirisN. OmerC. ChungJ.K. FullerJ. DagherR. ChandranS. HarwinP. KiselakT. ViolinJ. NicholsA. BistaP. STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema.J. Pharmacol. Exp. Ther.2023387221422510.1124/jpet.123.00174037643795
     [Google Scholar]
  106. MorabitoC. StevensC. ChungJ.K. DagherR. BistaP. BernardK. GustafsonP. GunsiorM. NicholsA. Initial results from a phase 1 single ascending dose clinical trial of STAR-0215, an investigational long-acting monoclonal antibody plasma kallikrein inhibitor for hereditary angioedema (HAE), in healthy subjects followed for at least 3 months.J. Allergy Clin. Immunol.20231512AB13610.1016/j.jaci.2022.12.426
     [Google Scholar]
  107. LamacchiaD. NappiE. MarzioV. LocatelliF. MessinaM.R. HefflerE. Hereditary angioedema: Current therapeutic management and future approaches.Curr. Opin. Allergy Clin. Immunol.202424425726510.1097/ACI.000000000000099238743499
     [Google Scholar]
/content/journals/rrct/10.2174/0115748871307432240930051749
Loading
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review
Rev. Recent Clin. Trials 20, 79 (2025); https://doi.org/10.2174/0115748871307432240930051749
/content/journals/rrct/10.2174/0115748871307432240930051749
/content/journals/rrct/10.2174/0115748871307432240930051749
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Angioedema; bradykinin; etiology; histamine; pathophysiology; urticaria

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test